DrugPatentWatch Database Preview
Binimetinib - Generic Drug Details
What are the generic drug sources for binimetinib and what is the scope of binimetinib freedom to operate?
Binimetinib
is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Binimetinib has one hundred and eighty-six patent family members in fifty countries.
One supplier is listed for this compound.
Summary for binimetinib
| International Patents: | 186 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 59 |
| Clinical Trials: | 20 |
| Patent Applications: | 147 |
| DailyMed Link: | binimetinib at DailyMed |
Synonyms for binimetinib
| 1073666-70-2 |
| 1201685-05-3 |
| 1417448-81-7 |
| 181R97MR71 |
| 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide |
| 5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami |
| 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |
| 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide |
| 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide |
| 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| 606143-89-9 |
| AB0095018 |
| AC-29023 |
| ACWZRVQXLIRSDF-UHFFFAOYSA-N |
| AKOS026750517 |
| AOB2072 |
| ARRY 162 |
| ARRY-162 |
| ARRY-162,MEK-162 |
| ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162 |
| ARRY-438162 |
| AS-16706 |
| BC600594 |
| Binimetinib (JAN/USAN) |
| Binimetinib (MEK162, ARRY-162, ARRY-438162) |
| Binimetinib [USAN:INN] |
| Binimetinib;MEK-162; ARRY-162;ARRY-438162 |
| C17H15BrF2N4O3 |
| cas:606143-89-9;MEK162 |
| CHEMBL3187723 |
| CS-0627 |
| D0C4LF |
| D10604 |
| DB11967 |
| DTXSID70209422 |
| EX-A1024 |
| FT-0697088 |
| GTPL7921 |
| HMS3652J14 |
| HY-15202 |
| J-516581 |
| KB-124302 |
| KB-78305 |
| KS-0000062X |
| MEK-162 |
| MEK162 |
| MEK162 (ARRY-162, ARRY-438162) |
| MEK162 (Arry-162) |
| MEK162(Binimetinib) |
| MLS006011180 |
| MolPort-028-720-357 |
| NCGC00345804-01 |
| NVP-MEK162 |
| QCR-138 |
| RL04283 |
| s7007 |
| SCHEMBL570088 |
| SMR004702949 |
| UNII-181R97MR71 |
| W-5894 |
| Y1468 |
| ZINC38460704 |
US Patents and Regulatory Information for binimetinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for binimetinib
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Croatia | P20140799 | ➤ Try a Free Trial |
| Hong Kong | 1070823 | ➤ Try a Free Trial |
| Taiwan | I338685 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
